Kura Oncology, Inc. (KURA)
| Market Cap | 1.35B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -114.29M |
| Shares Out | 66.28M |
| EPS (ttm) | -1.85 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 558,049 |
| Open | 20.64 |
| Previous Close | 20.96 |
| Day's Range | 19.93 - 20.83 |
| 52-Week Range | 15.12 - 43.00 |
| Beta | 1.83 |
| Analysts | Buy |
| Price Target | 44.57 (+122.1%) |
| Est. Earnings Date | Nov 4, 2021 |
About KURA
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidates are tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors and hematologic indications; and KO-539, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the ...
Financial Performance
Financial StatementsAnalyst Forecast
According to 8 analysts, the average rating for Kura Oncology stock is "Buy." The 12-month stock price forecast is 44.57, which is an increase of 122.07% from the latest price.
News
Kura Oncology to Participate in Two Upcoming Investor Conferences
SAN DIEGO, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment o...
Kura Oncology Reports Second Quarter 2021 Financial Results
– First patients dosed in Phase 1b expansion cohorts with menin inhibitor KO-539 –
Kura Oncology to Participate in Wedbush PacGrow Healthcare Virtual Conference
SAN DIEGO, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of...
Kura Oncology to Report Second Quarter 2021 Financial Results
SAN DIEGO, July 29, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of...
Kura Oncology Appoints Helen Collins, M.D. to Board of Directors
SAN DIEGO, July 29, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of...
Kura Oncology Announces Clinical Collaboration to Evaluate Tipifarnib in Combination with Alpelisib in Head and Neck ...
– Combination of tipifarnib and alpelisib shows robust activity in preclinical PDX models of HRAS and PIK3CA pathway dependent tumors –
Kura Oncology Doses First Patient in Phase 1b Expansion Cohorts with Menin Inhibitor KO-539
– Phase 1b expansion cohorts designed to enable refinement of recommended Phase 2 dose –
Kura Oncology to Participate in JMP Securities Life Sciences Conference
SAN DIEGO, June 10, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of...
Kura Oncology Appoints Carol Schafer to Board of Directors
SAN DIEGO, June 04, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of...
Kura Oncology to Participate in Cowen Virtual Oncology Innovation Summit
SAN DIEGO, May 13, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of ...
Kura Oncology Reports First Quarter 2021 Financial Results
– Menin inhibitor KO-539 continues to demonstrate compelling clinical activity, favorable safety/tolerability and a wide therapeutic window –
Kura Oncology to Report First Quarter 2021 Financial Results
SAN DIEGO, April 29, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment o...
Kura Oncology Announces Publication of Tipifarnib Phase 2 Data in Journal of Clinical Oncology
– Phase 2 RUN-HN trial showed ORR of 55%, median PFS of 5.6 months and median OS of 15.4 months in recurrent/metastatic HRAS mutant HNSCC –
Kura Oncology Receives FDA Breakthrough Therapy Tag For Tipifarnib In Head & Neck Cancer
The FDA has designated Breakthrough Therapy status to Kura Oncology Inc's (NASDAQ: KURA) tipifarnib, an orally bioavailable inhibitor of farnesyl transferase for head and neck cancer. The status covers ...
Kura Oncology Reports Fourth Quarter and Full Year 2020 Financial Results
– Preliminary clinical data for menin inhibitor KO-539 highlighted by single-agent activity in relapsed/refractory AML, including patients with NPM1 mutations –
Kura Oncology Receives FDA Breakthrough Therapy Designation for Tipifarnib in Head and Neck Squamous Cell Carcinoma
SAN DIEGO, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of...
Kura Oncology to Participate in Four Upcoming Investor Conferences
SAN DIEGO, Feb. 18, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of...
Kura Oncology to Report Fourth Quarter and Full Year 2020 Financial Results
SAN DIEGO, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of...
Kura Oncology to Participate in H.C. Wainwright BioConnect 2021 Conference
– Panel discussion on precision medicine to be hosted by former FDA Commissioner Dr. Scott Gottlieb – – Panel discussion on precision medicine to be hosted by former FDA Commissioner Dr. Scott Gottlieb –
Kura Oncology to Present at J.P. Morgan Healthcare Conference
SAN DIEGO, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of...
Kura Oncology Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares
SAN DIEGO, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of...
Kura Oncology: Advanced Precision Medicine Opportunity Excites, But Not Without Risks
Kura Oncology looks an attractive opportunity in the Precision Medicine / Targeted Therapies sector.
Kura Oncology to Participate in the JMP Securities Hematology Summit
SAN DIEGO, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of...
Kura Oncology Announces Pricing of $300 Million Public Offering of Common Stock
SAN DIEGO, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of...
Kura Oncology Announces Commencement of Public Offering of Common Stock
SAN DIEGO, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of...